NCT06469658Completed
Personalized Management of Type 2 Diabetes Using AI-Guided (GenAIS TM) Dietary Supplementation
Personalized Management of Type 2 Diabetes Using AI-Guided (GenAIS TM) Dietary Supplementation: A Randomized Controlled Clinical Trial
Source: ClinicalTrials.gov · Last updated 3 Jul 2024
Brief summary (registry, in English)
This randomized controlled trial investigates the effectiveness of AI-guided dietary supplement prescriptions compared to standard physician-guided prescriptions in managing Type 2 diabetes (T2D). The study includes 160 participants with T2D, aged 40-75, who will be randomly assigned to either the control group (standard physician-guided prescriptions) or the AI-guided group (prescriptions determined by GenAIS, an AI system by Triangel Scientific). The primary objective is to compare the reduction in HbA1c levels between the two groups over 6 months. Secondary outcomes include changes in fasting glucose, lipid profiles, body weight, BMI, hsCRP levels, and adherence to the dietary supplement regimen. The AI system integrates genetic, metabolic, and clinical data to provide personalized supplement recommendations, aiming to improve glycemic control and overall metabolic health.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 160 (actual)
- First submitted
- 12 Jun 2024
- Start date
- 2 Feb 2024
- Primary completion date
- 15 May 2024
- Lead sponsor
- S.LAB (SOLOWAYS)
- Diseases
- Type 2 diabetes
- NCT number
- NCT06469658
What you commit to
- Study type: Interventional
- Participants enrolled: 160
- From 2 Feb 2024 to the primary completion date, 15 May 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Type 1 diabetes or other specific types of diabetes.
- Significant renal, hepatic, or cardiovascular diseases.
Lab values
- Use of dietary supplements that affect glucose metabolism within the last 3 months.
Other
- Pregnancy or breastfeeding
Who the study is looking for
- Age between 40 and 75 years.
- Diagnosed with Type 2 diabetes (HbA1c between 7.0% and 10.0%).
- Stable anti-diabetic medication regimen for at least 3 months prior to the study.
- Willingness to provide genetic and metabolic data.
Age in the registry: 40 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Center of New Medical Technologies Coordinator of this site? Confirm its status | Novosibirsk | Russia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.